Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lang

Showing results (301-310 of 312) with videos related to

Pageof 32
Sort By:
Bone Marrow Transplantation|February 24, 2023
Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograftLuca Vinci, Christian Flotho, Peter Noellke, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Bone Marrow Transplantation|January 31, 2018
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, et al.
Haematologica|February 16, 2023
Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantationAmadeus T Heinz, Friso G J Calkoen, Alexander Derbich, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 10, 2026
European expert recommendations for comprehensive pre-treatment, treatment-phase and post-treatment care of patients with metachromatic leukodystrophy treated with autologous haematopoietic stem and progenitor cell gene therapyLucia Laugwitz, Francesca Fumagalli, Katharina Wehner, et al.
Blood|November 22, 2023
Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputationSvea Böhm, Katharina Wustrau, Jana Pachlopnik Schmid, et al.
Molecular Cancer|June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cellsMareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
Bone Marrow Transplantation|March 27, 2026
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMTSimone Cesaro, Chiara Garonzi, Gloria Tridello, et al.
Cells|December 11, 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 PatientsHalvard Bonig, Zyrafete Kuçi, Selim Kuçi, et al.
The Lancet. Oncology|June 27, 2024
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trialSelim Corbacioglu, Holger Lode, Susanne Ellinger, et al.
Pageof 32

Showing results (301-310 of 312) with videos related to

Sort By:
Pageof 32
Bone Marrow Transplantation|February 24, 2023
Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograftLuca Vinci, Christian Flotho, Peter Noellke, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Bone Marrow Transplantation|January 31, 2018
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, et al.
Haematologica|February 16, 2023
Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantationAmadeus T Heinz, Friso G J Calkoen, Alexander Derbich, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|July 10, 2026
European expert recommendations for comprehensive pre-treatment, treatment-phase and post-treatment care of patients with metachromatic leukodystrophy treated with autologous haematopoietic stem and progenitor cell gene therapyLucia Laugwitz, Francesca Fumagalli, Katharina Wehner, et al.
Blood|November 22, 2023
Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputationSvea Böhm, Katharina Wustrau, Jana Pachlopnik Schmid, et al.
Molecular Cancer|June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cellsMareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
Bone Marrow Transplantation|March 27, 2026
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMTSimone Cesaro, Chiara Garonzi, Gloria Tridello, et al.
Cells|December 11, 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 PatientsHalvard Bonig, Zyrafete Kuçi, Selim Kuçi, et al.
The Lancet. Oncology|June 27, 2024
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trialSelim Corbacioglu, Holger Lode, Susanne Ellinger, et al.
Pageof 32